Cargando…
Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
Acute myeloid leukemia (AML) is a molecularly heterogenous hematological malignancy, with one of the most common mutations being internal tandem duplication (ITD) of the juxtamembrane domain of the fms-like tyrosine kinase receptor-3 (FLT3). Despite the development of FLT3-directed tyrosine kinase i...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027903/ https://www.ncbi.nlm.nih.gov/pubmed/35453402 http://dx.doi.org/10.3390/antiox11040717 |
_version_ | 1784691483575582720 |
---|---|
author | Kannan, Sankaranarayan Irwin, Mary E. Herbrich, Shelley M. Cheng, Tiewei Patterson, LaNisha L. Aitken, Marisa J. L. Bhalla, Kapil You, M. James Konopleva, Marina Zweidler-McKay, Patrick A. Chandra, Joya |
author_facet | Kannan, Sankaranarayan Irwin, Mary E. Herbrich, Shelley M. Cheng, Tiewei Patterson, LaNisha L. Aitken, Marisa J. L. Bhalla, Kapil You, M. James Konopleva, Marina Zweidler-McKay, Patrick A. Chandra, Joya |
author_sort | Kannan, Sankaranarayan |
collection | PubMed |
description | Acute myeloid leukemia (AML) is a molecularly heterogenous hematological malignancy, with one of the most common mutations being internal tandem duplication (ITD) of the juxtamembrane domain of the fms-like tyrosine kinase receptor-3 (FLT3). Despite the development of FLT3-directed tyrosine kinase inhibitors (TKI), relapse and resistance are problematic, requiring improved strategies. In both patient samples and cell lines, FLT3-ITD raises levels of reactive oxygen species (ROS) and elicits an antioxidant response which is linked to chemoresistance broadly in AML. NF-E2–related factor 2 (NRF2) is a transcription factor regulating the antioxidant response including heme oxygenase -1 (HO-1), a heat shock protein implicated in AML resistance. Here, we demonstrate that HO-1 is elevated in FLT3-ITD-bearing cells compared to FLT3-wild type (WT). Transient knockdown or inhibitor-based suppression of HO-1 enhances vulnerability to the TKI, quizartinib, in both TKI-resistant and sensitive primary AML and cell line models. NRF2 suppression (genetically or pharmacologically using brusatol) results in decreased HO-1, suggesting that TKI-resistance is dependent on an active NRF2-driven pathway. In AML-patient derived xenograft (PDX) models, brusatol, in combination with daunorubicin, reduces leukemia burden and prolongs survival. Cumulatively, these data encourage further development of brusatol and NRF2 inhibition as components of combination therapy for refractory AML. |
format | Online Article Text |
id | pubmed-9027903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90279032022-04-23 Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy Kannan, Sankaranarayan Irwin, Mary E. Herbrich, Shelley M. Cheng, Tiewei Patterson, LaNisha L. Aitken, Marisa J. L. Bhalla, Kapil You, M. James Konopleva, Marina Zweidler-McKay, Patrick A. Chandra, Joya Antioxidants (Basel) Article Acute myeloid leukemia (AML) is a molecularly heterogenous hematological malignancy, with one of the most common mutations being internal tandem duplication (ITD) of the juxtamembrane domain of the fms-like tyrosine kinase receptor-3 (FLT3). Despite the development of FLT3-directed tyrosine kinase inhibitors (TKI), relapse and resistance are problematic, requiring improved strategies. In both patient samples and cell lines, FLT3-ITD raises levels of reactive oxygen species (ROS) and elicits an antioxidant response which is linked to chemoresistance broadly in AML. NF-E2–related factor 2 (NRF2) is a transcription factor regulating the antioxidant response including heme oxygenase -1 (HO-1), a heat shock protein implicated in AML resistance. Here, we demonstrate that HO-1 is elevated in FLT3-ITD-bearing cells compared to FLT3-wild type (WT). Transient knockdown or inhibitor-based suppression of HO-1 enhances vulnerability to the TKI, quizartinib, in both TKI-resistant and sensitive primary AML and cell line models. NRF2 suppression (genetically or pharmacologically using brusatol) results in decreased HO-1, suggesting that TKI-resistance is dependent on an active NRF2-driven pathway. In AML-patient derived xenograft (PDX) models, brusatol, in combination with daunorubicin, reduces leukemia burden and prolongs survival. Cumulatively, these data encourage further development of brusatol and NRF2 inhibition as components of combination therapy for refractory AML. MDPI 2022-04-05 /pmc/articles/PMC9027903/ /pubmed/35453402 http://dx.doi.org/10.3390/antiox11040717 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kannan, Sankaranarayan Irwin, Mary E. Herbrich, Shelley M. Cheng, Tiewei Patterson, LaNisha L. Aitken, Marisa J. L. Bhalla, Kapil You, M. James Konopleva, Marina Zweidler-McKay, Patrick A. Chandra, Joya Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy |
title | Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy |
title_full | Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy |
title_fullStr | Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy |
title_full_unstemmed | Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy |
title_short | Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy |
title_sort | targeting the nrf2/ho-1 antioxidant pathway in flt3-itd-positive aml enhances therapy efficacy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027903/ https://www.ncbi.nlm.nih.gov/pubmed/35453402 http://dx.doi.org/10.3390/antiox11040717 |
work_keys_str_mv | AT kannansankaranarayan targetingthenrf2ho1antioxidantpathwayinflt3itdpositiveamlenhancestherapyefficacy AT irwinmarye targetingthenrf2ho1antioxidantpathwayinflt3itdpositiveamlenhancestherapyefficacy AT herbrichshelleym targetingthenrf2ho1antioxidantpathwayinflt3itdpositiveamlenhancestherapyefficacy AT chengtiewei targetingthenrf2ho1antioxidantpathwayinflt3itdpositiveamlenhancestherapyefficacy AT pattersonlanishal targetingthenrf2ho1antioxidantpathwayinflt3itdpositiveamlenhancestherapyefficacy AT aitkenmarisajl targetingthenrf2ho1antioxidantpathwayinflt3itdpositiveamlenhancestherapyefficacy AT bhallakapil targetingthenrf2ho1antioxidantpathwayinflt3itdpositiveamlenhancestherapyefficacy AT youmjames targetingthenrf2ho1antioxidantpathwayinflt3itdpositiveamlenhancestherapyefficacy AT konoplevamarina targetingthenrf2ho1antioxidantpathwayinflt3itdpositiveamlenhancestherapyefficacy AT zweidlermckaypatricka targetingthenrf2ho1antioxidantpathwayinflt3itdpositiveamlenhancestherapyefficacy AT chandrajoya targetingthenrf2ho1antioxidantpathwayinflt3itdpositiveamlenhancestherapyefficacy |